Immune checkpoint inhibitor combinations: challenges and future perspectives
Immuno-oncology agents plus tyrosine kinase inhibitors?
Are liquid biopsies a viable alternative to tumor biopsies?
Targeting PD-1 and PD-L1 for lung cancer therapy
Joseph Paul Eder
Managing the adverse events of immune checkpoint inhibitors